Imlunestrant (LY-3484356) tosylate is an orally active, potent and selective cancer (EEC)[1][2].
LY3484356 显示出良好药代动力学 (PK) 特性，包括在 ESR1 突变体中的抗肿瘤活性[1]。
[1]. Komal L. Jhaveri, et al. A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study. 2021 ASCO Annual Meeting I.
[2]. Cristina Hernando, et al. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. Int. J. Mol. Sci. 2021, 22(15), 7812.